David R. Margrave - 18 Dec 2025 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role: Chief Financial Officer
Signature: /s/ David R. Margrave
Issuer symbol: LTRN
Transactions as of: 18 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 22 Dec 2025, 16:05:25 UTC
Previous filing: 23 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Margrave David R.	Chief Financial Officer	1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS	/s/ David R. Margrave	22 Dec 2025	0001813162

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LTRN	Stock Option (Right to Buy)	Award	$0	+20,000		$0.000000	20,000	18 Dec 2025	Common Stock	20,000	$3.24	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026.